RxDoctor Payments Data

Jade Jones

Psychiatry · Saint Charles, ILNPI 1447771787

Payments from drug & device makers

$4,214in general payments, 2019–2025

Across 196 payments — averaging $21.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Otsuka America Pharmaceutical, Inc.$717
  • Alkermes, Inc.$429
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$325
  • Neurocrine Biosciences, Inc.$208
  • Jazz Pharmaceuticals Inc.$183
  • plus $1K from 16 others

What the payments were for

  • Food & beverage$4,15799%
  • Education$571%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,214 in reported general payments places this provider in the 85th percentile of 1,344 psychiatry providers in Illinois.

See all psychiatry providers in Illinois

Medicare billing

Part B allowed, 2024
$31,894
Medicare patients
122
Services billed
490

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine23$93,770
VraylarCariprazine Hcl13$34,362
Aripiprazole66$7,775
Divalproex Sodium131$7,546
Olanzapine198$5,640
Quetiapine Fumarate134$4,716
Risperidone228$4,609
Lurasidone Hcl104$4,581
Divalproex Sodium ErDivalproex Sodium91$3,510
Paliperidone ErPaliperidone25$3,356
Trazodone Hcl226$3,246
Lorazepam249$2,627
Haloperidol56$2,404
Benztropine Mesylate141$2,141
Fluoxetine Hcl172$2,069

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo$43$93,77023 claims
AbbVieVraylar$1,104$34,36213 claims
Almatica Pharma LLCSertraline Hcl$137$1,957204 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,344 psychiatry providers in Illinois.

Other psychiatry in Saint Charles

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →